Topics in Antiviral Medicine Volume 25 Issue 2 May/June 2017
Topics in Antiviral Medicine 25 Issue 2 May/June 2017
Working Document, September 2017
Adapted from a fact sheet on TB from the International Council of Nurse’s Global TB/MDR-TB Resource Centre at: http://www.icn.ch/tb/stigma.htm.
Accessed November 2017
Time for recognition of lay counsellors
Accessed November 2017
End TB.
Accessed in November 2017.
Direct acting antivirals (DAAs) have revolutionized treatment for hepatitis C. Combi-
nations of DAAs can cure infection with HCV in 12 weeks, are highly effective and
have limited side-effects. Affordability of DAAs has improved significantly, but access remains lim-
i...ted. Initially, due to their high prices, affordability of DAAs was limited in high-, middle- and low-
income countries alike. Now there is a divide between those countries where, because of intellectual
property barriers, prices have remained (very) high and other countries where generics are, or can be,
available at much lower prices. The result is a dual market
more
TB and HIV services offered to a patient at the same time and location (Patient Centered Care)
National Tuberculosis and Leprosy Control Program
Practical Guidance for collaborative interventions
MSF International AIDS Working Group
The way Forward
Executive Summary
SDG target 3.3: by 2030, end the epidemics of AIDS, tuberculosis, malaria and neglected tropical diseases and combat hepatitis, waterborne diseases and other communicable diseases.